Eric Devroe - Nov 9, 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Operating Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Nov 9, 2022
Transactions value $
$0
Form type
3
Date filed
11/9/2022, 07:30 PM
Next filing
Nov 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRV Common Stock 20.3K Nov 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 106K $1.04 Direct F1
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 94.6K $3.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original grant was for 126,115 shares, which was partially exercised for 20,275 shares of common stock. Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2 The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney